Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 18/20 | 0.82 |
| ▸ | HRH1 | P35367 | 16/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416052 | 0.93 | HRH1 (0.71) | CCR3HRH1KCNH2CHRM2MEN1 | |
| SCHEMBL5403946 | 0.92 | CCR3 (0.86) | CCR3HRH1KCNH2 | |
| SCHEMBL5420364 | 0.92 | CCR3 (0.86) | CCR3HRH1KCNH2 | |
| SCHEMBL5406026 | 0.90 | CCR3 (0.84) | CCR3HRH1KCNH2 | |
| SCHEMBL5403357 | 0.90 | CCR3 (1.00) | CCR3HRH1KCNH2 | |
| SCHEMBL5417495 | 0.89 | CCR3 (0.81) | CCR3HRH1KCNH2CHRM2 | |
| SCHEMBL5409191 | 0.89 | CCR3 (0.81) | CCR3HRH1KCNH2 | |
| SCHEMBL5414859 | 0.86 | HRH1 (0.61) | CCR3HRH1KCNH2CHRM2MEN1 | |
| SCHEMBL5414171 | 0.86 | HRH1 (0.83) | CCR3HRH1KCNH2 | |
| SCHEMBL5418920 | 0.85 | CCR3 (0.78) | CCR3HRH1KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | claimed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | claimed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | claimed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| EP-1404667-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004487-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR1, CCR3, CCRL2 | CCR3 2/4885HRH1 25/4885KCNH2 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.